Literature DB >> 18928666

Uterine sarcoma 2008.

Jeff F Lin1, Brian M Slomovitz.   

Abstract

Uterine sarcomas are a group of rare and usually aggressive soft tissue cancers. They have a wide range of histologic appearances, from myomatous to osteous to stromal. The three major subtypes of uterine sarcomas (listed in decreasing order of incidence) are carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma. Most patients with uterine sarcomas are middle- to older-aged women who present with abnormal uterine bleeding or pelvic mass, which may be confused with leiomyoma. Surgery--including hysterectomy and resection of disease--serves as the main treatment modality. Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may be due to the lack of good randomized controlled trials of sufficient size because of uterine sarcomas' rare and aggressive nature. For patients with metastatic recurrent disease, aggressive therapy is limited by low response rates and limited duration of response. For patients with uterine sarcomas, enrollment in clinical trials is strongly encouraged.

Entities:  

Mesh:

Year:  2008        PMID: 18928666     DOI: 10.1007/s11912-008-0077-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  40 in total

1.  Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study.

Authors:  E Sartori; L Bazzurini; A Gadducci; F Landoni; A Lissoni; T Maggino; P Zola; B La Face
Journal:  Gynecol Oncol       Date:  1997-10       Impact factor: 5.482

2.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.

Authors:  Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482

3.  Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

Authors:  Howard D Homesley; Virginia Filiaci; Maurie Markman; Pincas Bitterman; Lynne Eaton; Larry C Kilgore; Bradley J Monk; Frederick R Ueland
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

4.  A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.

Authors:  G A Omura; J A Blessing; F Major; S Lifshitz; C E Ehrlich; C Mangan; J Beecham; R Park; S Silverberg
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

5.  Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus.

Authors:  Mark E Sherman; Susan S Devesa
Journal:  Cancer       Date:  2003-07-01       Impact factor: 6.860

6.  Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience.

Authors:  C F Verschraegen; A Vasuratna; C Edwards; R Freedman; A P Kudelka; C Tornos; J J Kavanagh
Journal:  Oncol Rep       Date:  1998 Jul-Aug       Impact factor: 3.906

7.  Sarcomas of the uterus: a clinicopathologic study of 119 patients.

Authors:  K V Kahanpää; T Wahlström; P Gröhn; E Heinonen; U Nieminen; O Widholm
Journal:  Obstet Gynecol       Date:  1986-03       Impact factor: 7.661

8.  The utility of preoperative endometrial sampling for the detection of uterine sarcomas.

Authors:  Nisha Bansal; Thomas J Herzog; William Burke; Carmel J Cohen; Jason D Wright
Journal:  Gynecol Oncol       Date:  2008-04-29       Impact factor: 5.482

9.  Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.

Authors:  Daniel S Kapp; Jacob Y Shin; John K Chan
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

10.  Female genital tract cancer.

Authors:  C E Platz; J A Benda
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

View more
  10 in total

1.  A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.

Authors:  Weiwei Shan; Patricia Y Akinfenwa; Kari B Savannah; Nonna Kolomeyevskaya; Rudolfo Laucirica; Dafydd G Thomas; Kunle Odunsi; Chad J Creighton; Dina C Lev; Matthew L Anderson
Journal:  Clin Cancer Res       Date:  2012-04-25       Impact factor: 12.531

Review 2.  Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Nobuyoshi Hiraoka; Yae Kanai; Tanri Shiozawa; Susumu Tonegawa; Ikuo Konishi
Journal:  Protein Cell       Date:  2010-08-28       Impact factor: 14.870

3.  Incidence of occult leiomyosarcoma in presumed morcellation cases: a database study.

Authors:  Ana M Rodriguez; Mehmet R Asoglu; Muhammet Erdal Sak; Alai Tan; Mostafa A Borahay; Gokhan S Kilic
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2015-11-28       Impact factor: 2.831

4.  Molecular Approach to Uterine Leiomyosarcoma: LMP2-Deficient Mice as an Animal Model of Spontaneous Uterine Leiomyosarcoma.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Nobuyoshi Hiraoka; Yae Kanai; Tanri Shiozawa; Susumu Tonegawa; Ikuo Konishi
Journal:  Sarcoma       Date:  2011-03-08

5.  Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Nobuyoshi Hiraoka; Mari Kasai; Tomoyuki Ichimura; Tamotsu Sudo; Yoh-Ichi Tagawa; Ryuichiro Nishimura; Osamu Ishiko; Yae Kanai; Nobuo Yaegashi; Hiroyuki Aburatani; Tanri Shiozawa; Ikuo Konishi
Journal:  Sci Rep       Date:  2011-12-05       Impact factor: 4.379

6.  Involvement of proteasome β1i subunit, LMP2, on development of uterin leiomyosarcma.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Nobuyoshi Hiraoka; Mari Kasai; Tomoyuki Ichimura; Satoru Nagase; Osamu Ishiko; Tanri Shiozawa; Yae Kanai; Nobuo Yaegashi; Hiroyuki Aburatani; Susumu Tonegawa; Ikuo Konishi
Journal:  N Am J Med Sci       Date:  2011-09

7.  Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage.

Authors:  Tianhui Chen; Lina Jansen; Adam Gondos; Meike Ressing; Bernd Holleczek; Alexander Katalinic; Hermann Brenner
Journal:  BMC Cancer       Date:  2012-03-30       Impact factor: 4.430

Review 8.  MRI of the endometrium - from normal appearances to rare pathology.

Authors:  Roxana Pintican; Vlad Bura; Marta Zerunian; Janette Smith; Helen Addley; Susan Freeman; Damiano Caruso; Andrea Laghi; Evis Sala; Mercedes Jimenez-Linan
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.629

9.  Potential biomarker for human uterine leiomyosarcoma.

Authors:  Takuma Hayashi; Akiko Horiuchi; Hiroyuki Aburatani; Osamu Ishiko; Nobuo Yaegashi; Yae Kanai; Dorit Zharhary; Tanri Shiozawa; Susumu Tonegawa; Ikuo Konishi
Journal:  J Clin Med Res       Date:  2014-07-28

10.  Ultrasonographic findings of low-grade endometrial stromal sarcoma of the uterus with a focus on cystic degeneration.

Authors:  Ga Eun Park; Sung Eun Rha; Soon Nam Oh; Ahwon Lee; Keun Ho Lee; Mee-Ran Kim
Journal:  Ultrasonography       Date:  2015-10-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.